<code id='1079DC644E'></code><style id='1079DC644E'></style>
    • <acronym id='1079DC644E'></acronym>
      <center id='1079DC644E'><center id='1079DC644E'><tfoot id='1079DC644E'></tfoot></center><abbr id='1079DC644E'><dir id='1079DC644E'><tfoot id='1079DC644E'></tfoot><noframes id='1079DC644E'>

    • <optgroup id='1079DC644E'><strike id='1079DC644E'><sup id='1079DC644E'></sup></strike><code id='1079DC644E'></code></optgroup>
        1. <b id='1079DC644E'><label id='1079DC644E'><select id='1079DC644E'><dt id='1079DC644E'><span id='1079DC644E'></span></dt></select></label></b><u id='1079DC644E'></u>
          <i id='1079DC644E'><strike id='1079DC644E'><tt id='1079DC644E'><pre id='1079DC644E'></pre></tt></strike></i>

          focus

          focus

          author:focus    Page View:9844
          Adobe

          The Biden administration moved Wednesday to force insurance companies to give specific reasons for denying coverage, and to speed up the pre-approval process in general.

          The new rule applies to health insurance companies that offer Medicare, Medicaid, Children’s Health Insurance Program, and Obamacare plans. It concerns so-called prior authorization requests, and will require insurers to return urgent requests within 72 hours and non-urgent requests within seven days.

          advertisement

          The changes are a win for patients seeking care, but also for health care providers like hospitals and physicians. Executives from California-based Sutter Health, Massachusetts General Brigham, and others repeatedly cited the rise in insurer denials since the pandemic at last week’s J.P. Morgan Healthcare conference.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Gilead acquiring CymaBay and its liver disease drug for $4.3 billion
          Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

          YichuanCao/SipaUSAGileadSciencessaidMondayitwillacquireCymaBayTherapeuticsfor$4.3billion,addinganewt

          read more
          23andMe had bad news about my health. I wish a person had delivered it
          23andMe had bad news about my health. I wish a person had delivered it

          ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

          read more

          BioAge raises $170M for combination therapy with Zepbound

          Illustration:STAT;Source:EliLilly/APACaliforniabiotechdevelopingacombinationtherapywiththeobesitydru